Nonhuman Primate Reagent Resource

非人类灵长类动物试剂资源

• 批准号: 9312774
• 负责人: KEITH A. REIMANN
• 金额: $ 176.9万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-29 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9312774
• 关键词: Animal Model; Antibodies; Autoimmune Diseases; Biological Response Modifier Therapy; Budgets; Communicable Diseases; Communities; Data; Databases; Development; Diagnostic; Discipline; Disease; Disease model; Engineering; Formulation; Health Services Accessibility; Human; Immunologics; In Vitro; Lymphocyte Subset; Modeling; Organ Transplantation; Pathogenesis; Primates; Production; Quality Control; Reagent; Recombinant Antibody; Records; Research; Research Personnel; Resources; Role; Scientific Advances and Accomplishments; Testing; Therapeutic; Translational Research; United States National Institutes of Health; Vaccines; expression vector; immune function; in vivo; large scale production; nonhuman primate; novel therapeutics; outreach; programs; response; tool; web site

Nonhuman primates (NHPs) serve a crucial role in translational research as animal models for exploring the pathogenesis of infectious and noninfectious diseases, and for testing of biologic therapies and vaccines. While many human diagnostic immunologic reagents cross react with the primate species commonly employed in translational research, gaps exist for a substantial number of reagent targets. Furthermore, antibodies that target specific immune functions or deplete specific lymphocyte subpopulations in vivo have proven valuable in defining disease mechanisms or can be used as proof-of-concept for new therapies. For the past 15 years, the NIH Nonhuman Primate Reagent Resource has responded to needs of the scientific community by developing, manufacturing and distributing NHP- specific reagents for in vitro diagnostics and for in vivo use. Utilization of this resource has grown dramatically since this program's inception. During the last budget year, we fulfilled 500 reagent requests from 126 investigators and distributed over 300 grams of recombinant antibody for administration to NHPs. Taking advantage of scientific advances and technological improvements in antibody development, engineering, expression and vectoring, we will continue to support the scientific community utilizing NHP models across all scientific disciplines.

非人类灵长类动物（NHP）在转化研究中起着至关重要的作用 用于探索传染病和非感染疾病的发病机理，并测试 生物疗法和疫苗。而许多人类诊断免疫学试剂交叉 与转化研究中通常使用的灵长类动物反应，存在差距 大量的试剂靶标。此外，靶向特定免疫的抗体 在体内的功能或耗尽的特定淋巴细胞亚群已证明有价值 定义疾病机制，或用作新疗法的概念验证。 在过去的15年中，NIH非人类灵长类试剂资源已回应 科学界的需求是通过开发，制造和分发NHP- 用于体外诊断和体内使用的特定试剂。此资源的利用 自从该计划的成立以来，急剧成长。在上一个预算年中，我们实现了 来自126位调查人员的500个试剂请求，并分发了超过300克的重组 用于NHP的抗体。 利用科学进步和抗体的技术改进 开发，工程，表达和矢量，我们将继续支持 科学界利用所有科学学科的NHP模型。